JP2004083588A5 - - Google Patents

Download PDF

Info

Publication number
JP2004083588A5
JP2004083588A5 JP2003288432A JP2003288432A JP2004083588A5 JP 2004083588 A5 JP2004083588 A5 JP 2004083588A5 JP 2003288432 A JP2003288432 A JP 2003288432A JP 2003288432 A JP2003288432 A JP 2003288432A JP 2004083588 A5 JP2004083588 A5 JP 2004083588A5
Authority
JP
Japan
Prior art keywords
hmg
coa reductase
reductase inhibitor
bile acids
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003288432A
Other languages
English (en)
Japanese (ja)
Other versions
JP4454985B2 (ja
JP2004083588A (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2003288432A priority Critical patent/JP4454985B2/ja
Priority claimed from JP2003288432A external-priority patent/JP4454985B2/ja
Publication of JP2004083588A publication Critical patent/JP2004083588A/ja
Publication of JP2004083588A5 publication Critical patent/JP2004083588A5/ja
Application granted granted Critical
Publication of JP4454985B2 publication Critical patent/JP4454985B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003288432A 2002-08-08 2003-08-07 血液脂質を低下させるための医薬組成物 Expired - Fee Related JP4454985B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2003288432A JP4454985B2 (ja) 2002-08-08 2003-08-07 血液脂質を低下させるための医薬組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002231618 2002-08-08
JP2003288432A JP4454985B2 (ja) 2002-08-08 2003-08-07 血液脂質を低下させるための医薬組成物

Publications (3)

Publication Number Publication Date
JP2004083588A JP2004083588A (ja) 2004-03-18
JP2004083588A5 true JP2004083588A5 (cg-RX-API-DMAC7.html) 2006-09-14
JP4454985B2 JP4454985B2 (ja) 2010-04-21

Family

ID=32072333

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003288432A Expired - Fee Related JP4454985B2 (ja) 2002-08-08 2003-08-07 血液脂質を低下させるための医薬組成物

Country Status (1)

Country Link
JP (1) JP4454985B2 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0618379A2 (pt) * 2005-11-08 2011-08-30 Ranbaxy Lab Ltd processo para preparação do hemi-sal de cálcio do ácido (3r,5r) -7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroxime tilfenilamino) carbonil]-pirrol-1-il] -3, 5-diidroxi heptanóico
ES2924236T3 (es) * 2017-05-02 2022-10-05 Lubrizol Advanced Mat Inc Composiciones farmacéuticas altamente cargadas de liberación prolongada mejoradas
JP2020186223A (ja) * 2019-05-09 2020-11-19 救心製薬株式会社 牛黄及び/又は鹿茸及び/又は胆汁酸を含有する組成物

Similar Documents

Publication Publication Date Title
JP2022116083A5 (cg-RX-API-DMAC7.html)
JP2010047616A5 (cg-RX-API-DMAC7.html)
AU2004208615B2 (en) Medicine for prevention of and treatment for arteriosclerosis and hypertension
RU2022100434A (ru) Фармацевтические композиции, содержащие epa и сердечно-сосудистое средство, и способы их применения
HRP20241674T1 (hr) 6'-[[(1s,3s)-3-[[5-(difluormetoksi)-2-pirimidinil]amino]ciklopentil]amino][1(2h),3'-bipiridin]-2-on kao inhibitor pcsk9 i postupci njegove upotrebe
MX2009003920A (es) Estatina y acidos grasos omega 3 para reducir los niveles de apo b.
NZ552389A (en) Statin pharmaceutical compositions and related methods of treatment
PL362477A1 (en) Hmg-coa reductase inhibitors and their use as medicaments for the treatment of cholesterol related diseases
FI3448426T3 (fi) Menetelmiä familiaalista hyperkolesterolemiaa sairastavien potilaiden hoitoon
JP2004537553A5 (cg-RX-API-DMAC7.html)
JP2008509132A5 (cg-RX-API-DMAC7.html)
PL377344A1 (pl) Lekarstwo do profilaktyki i leczenia miażdżycy tętnic i nadciśnienia
JP2016518338A5 (cg-RX-API-DMAC7.html)
RU2017106896A (ru) Антиметаногенные композиции и их применение
IL292829A (en) Fixed dose combinations containing etc1002 and one or more statins to treat or reduce cardiovascular risk
WO2005046662A3 (en) Hdl-boosting combination therapy complexes
JP2006512361A5 (cg-RX-API-DMAC7.html)
AR081032A1 (es) Formulacion farmaceutica en forma de comprimidos de dos capas que comprenden inhibidor de hmg-coa reductasa e irbesartan
RU2018133690A (ru) Лечение пациентов с гомозиготной семейной гиперхолестеринемией, получающих липидоснижающую терапию
WO2000048626A3 (en) Aerosol compositions of hmg-coa reductase inhibitors for inhibiting inflammation associated with pulmonary disease
NZ603207A (en) Combination of hmg-coa reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases
IL178475A0 (en) Sustained release formulation for oral administration of hmg-coa reductase inhibitor and method for the preparation thereof
JP2007530528A5 (cg-RX-API-DMAC7.html)
JP2008513379A5 (cg-RX-API-DMAC7.html)
JP2006176498A5 (cg-RX-API-DMAC7.html)